Stockreport

Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity [Yahoo! Finance]

Elevai Labs, Inc.  (ELAB) 
PDF functional (rotarod test) improvements in the dystrophic features of mdx mice, a mouse model of Duchenne muscular dystrophy (DMD) Elevai believes that EL-22 has the po [Read more]